Simpson Thacher represented the underwriters, led by Goldman Sachs & Co. LLC, BNP PARIBAS, HSBC, Mizuho, among others in connection with a registered offering of €3.3 billion in Notes by Pfizer, Inc.’s (“Pfizer”) wholly-owned subsidiary, Pfizer Netherlands International Finance B.V. (the “Issuer”). The Notes were issued in four series with maturities ranging from 2029 to 2045, with proceeds intended to be used for general corporate purposes. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer.
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Pfizer works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time, collaborating with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
The Simpson Thacher team included Joseph Kaufman, Jonathan Ozner, Kirsten Harmon, Shuhan Zhang and Harrison Gordon (Capital Markets), Russell Light and Michael Mann (Tax), Corina Holland (Intellectual Property), Jamin Koslowe and Guanxiong Xu (Executive Compensation and Benefits) and Jennie Getsin (Blue Sky).